Insulet Corporation (NASDAQ: PODD) — FY 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. The filing also reports fourth-quarter results. All financial figures are in U.S. dollars.
Business context
Insulet develops, manufactures and sells the OmniPod tubeless insulin-management system, alongside diabetes supplies distributed through its Neighborhood Diabetes business. U.S. sales of the smaller, lighter next-generation OmniPod began in 2013; the U.S. customer transition was completed by year-end. The company also sells internationally through distributors.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $247.1 million | $211.4 million |
| Gross profit / gross margin | $112.4 million / 45.5% | $92.3 million / 43.7% |
| Operating loss / operating margin | $29.1 million / 11.8% of revenue | $36.0 million / 17.0% of revenue |
| Net loss | $45.0 million | $51.9 million |
| Net loss per share | $0.83 | $1.08 |
| Cash provided by (used in) operations | $3.3 million | ($29.1 million) |
| Capital expenditures | $7.3 million | $11.0 million |
| Cash and cash equivalents at year-end | $149.7 million | $57.3 million |
| Working capital at year-end | $155.8 million | $61.7 million |
Revenue grew 17%, driven mainly by continued OmniPod adoption in the U.S. and internationally; this was partly offset by lost Medicare mail-order testing-supply sales. Gross margin improved as OmniPod unit costs declined with raw-material savings, volume discounts and higher manufacturing overhead absorption. Operating expenses rose 10%, including higher legal and administrative costs. Net loss improved, but the company remained unprofitable.
At year-end, principal outstanding on the 3.75% convertible notes was $143.8 million, due in June 2016; their reported carrying value was $113.7 million after debt discount. Capital-lease obligations were $8.0 million. The company says cash, together with expected product-sale cash generation, should cover projected operating and debt-service requirements for at least the next twelve months. It also identifies the 2016 note repayment as a potential financing need.
Fourth quarter: Revenue was $68.5 million, gross profit $33.0 million, and net loss $2.5 million, compared with revenue of $57.8 million, gross profit of $25.3 million, and net loss of $10.2 million in Q4 2012. Q4 2013 net loss included $1.4 million of other income from the fair-value change in a notes call feature.
Changes, outlook and material matters
- Neighborhood Diabetes was excluded from the Medicare competitive-bidding program for certain mail-order testing supplies from July 1, 2013. Management says this reduced 2013 results and will continue to affect results in 2014 and beyond.
- In 2013, Insulet raised approximately $92.8 million net through a common-stock offering. Shares outstanding increased, and the company also issued shares in connection with extinguishing the remaining 5.375% notes.
- A Medtronic patent dispute was settled in September 2013. Insulet recorded approximately $10 million of expense for the one-time payment and related legal fees. It also recorded a $2.5 million charge for manufacturing equipment no longer expected to be used. The 5.375% notes were repaid in full during 2013.
- Management expects 2014 revenue to increase with U.S. customer growth and international expansion, while noting dependence on sales execution and sufficient OmniPod production. It expects R&D and sales and marketing spending to rise, G&A to decline from 2013, and near-term net losses to continue. Manufacturing capacity was described as sufficient for expected 2014 demand.
- Development priorities include LifeScan OneTouch integration (510(k) filing made in Q1 2014), a concentrated-insulin Type 2 product with Eli Lilly (targeting a 510(k) filing in the second half of 2014), continuous sensing, a new PDM and pharmaceutical delivery partnerships.
- Key risks include reliance on a principal product and third-party manufacturing in China, sole-source suppliers, reimbursement and regulatory changes, competition, patient retention and collection risk. The filing reports a Massachusetts Attorney General inquiry into historical Neighborhood Diabetes prescription-refill practices; management said an adverse outcome was not probable at year-end, but could not assess the ultimate outcome. Insulet also reported no material financial exposure from the remaining BD patent claims, while noting litigation uncertainty.
- Ernst & Young issued an unqualified opinion on the financial statements and internal controls. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Important facts for investors to verify
- Whether revenue growth and unit-cost reductions continue to improve gross margin and move the business toward operating profitability.
- The magnitude of the ongoing Medicare competitive-bidding impact on Neighborhood Diabetes, and the business’s exposure to reimbursement rates and payor concentration.
- Cash generation, capital needs and the company’s plan to address the $143.8 million notes due in 2016, including potential conversion or refinancing.
- Execution and regulatory timing for the planned product developments, and whether manufacturing capacity and supplier arrangements can support growth.
- Developments in the Massachusetts inquiry and any remaining litigation or other contingencies.